Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

04/20/2012 | 08:16pm US/Eastern
Recommend:
0

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

XIANYANG, China, April 20, 2012/PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in Chinafor a variety of diseases and conditions, today announced that it has received written notification from the Nasdaq Listing Qualifications department that it has regained compliance with the minimum bid price requirement of $1.00per share for continued listing of its common stock on The NASDAQ Global Market set forth in Nasdaq Listing Rule 5450(a)(1), as its common shares achieved a closing bid price of $1.00or more for 10 consecutive business days prior to the compliance deadline of April 23, 2012and this matter is now closed.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to maintain its ongoing compliance with the Nasdaq continued listing requirements, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:




BioStar Pharmaceuticals, Inc. 

The Equity Group, Inc.

Zack Pan, CFO 

Lena Cati

Tel: 405-996-8829 

Tel: 212 836-9611

Email: zpan@aoxing-group.com

Email: lcati@equityny.com

SOURCE Biostar Pharmaceuticals, Inc.

distributed by
Recommend :
0
React to this article
Latest news
Date Title
3m ago ICHOR COAL NV : IchorCoal acquires 29.99 percent stake in Universal Coal plc
9m ago ICHOR COAL NV : DGAP-News: ICHOR Coal N.V.: IchorCoal acquires 29.99 percent stake in Universal Coal plc
13m ago BHG BRAZIL HOSPITALITY : Notice to the Market - BOFA Equity Holding - 09/01/2014
15m ago GREENFLAG VENTURES : Announces Executive Leadership Update
28m ago MEDICINOVA : to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)
28m ago LOJAS MARISA : Marisa closes 2 stores
28m ago BANCO PAN : Notice to the Market - Brazilian Central Bank approves Capital Increase
29m ago AUD/USD TECHNICAL ANALYSIS : Bearish Turn Signal Emerges
29m ago NZD/USD TECHNICAL ANALYSIS : Trying to Carve Out a Bottom
29m ago The Dog Breeds Bible Publishes Characteristics of Hybrid Dogs
Latest news
Advertisement
Hot News 
FORBIDDEN TECHNOLOGIES : Launches Alpha Test Of 'Eva' Video Platform
PERFORM : Final cash offer
WORTHINGTON : Re Agreement
SEEING MACHINES : Trading Up 25% As It Teams With Takata Corp
SHANTA GOLD : Reaffirms Production Guidance As First-Half Profit Rises
Most Read News
1h ago STUART OLSON : announces sale of Broda Construction
1h ago FORMFACTOR : Raises Third Quarter Guidance Range
1h ago EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
1h ago Los Angeles Hotel Operators Express Concern Over Contrary Wage Proposals
1h ago OLEO E GAS PARTICIPACOES : OGpar Receives Opinion on its Financial Statements of 2013
Most recommended articles
12h agoDJZambia Copper Miners Say Crippled by Unpaid $600 Million Tax Refund-Mines Body
3d ago S&P 500 edges up to set new record; best month since Feb
29m ago AUD/USD TECHNICAL ANALYSIS : Bearish Turn Signal Emerges
29m ago NZD/USD TECHNICAL ANALYSIS : Trying to Carve Out a Bottom
54m ago EUR/JPY TECHNICAL ANALYSIS : Key Support Above 136.00 Mark
Dynamic quotes  
ON
| OFF